Sign in Subscribe

CRC Research Update — March 20, 2026

Today's colorectal cancer research highlights

The CRC Digest

Curated CRC research — accessible, accurate, actionable

Friday, March 20, 2026

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key
◆ TRIAL DATA clinical trial results, efficacy data, survival endpoints ▸ TREATMENT new treatment options, regimen changes, combination therapies ● REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes ◇ RESEARCH cancer biology, biomarker discoveries, resistance pathways ▪ SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling ♥ LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support
  • Negative Screening Colonoscopy Reduces CRC Risk for Years

    A population-based study found that individuals with a negative screening colonoscopy had significantly lower colorectal cancer incidence compared to those who didn't follow up after a positive fecal test, supporting extended screening intervals after clear results. (JAMA Network Open)

  • Lenvatinib Plus Pembrolizumab Shows Activity in Previously Treated Advanced CRC

    Phase II results from the LEAP-005 study evaluated the combination of lenvatinib and pembrolizumab in patients with previously treated advanced colorectal cancer, though specific efficacy data and patient population details were not provided in the abstract. (Clinical Colorectal Cancer)

  • AI System for Polyp Detection Tested in Screening Program

    A randomized trial evaluated an artificial intelligence system for detecting and characterizing lesions during colonoscopy in patients with positive fecal immunochemical tests, though effectiveness results in this screening context remain under investigation. (Colorectal Diseases)

  • Targeting WIP1 May Enhance Immunotherapy Response

    Researchers identified WIP1 as a driver of immunosuppression in colorectal cancer and found that targeting it may reprogram the tumor microenvironment to improve immune checkpoint inhibitor response, though this is preclinical research. (Cell Death & Differentiation)

Stay informed as research continues to advance our understanding of colorectal cancer screening, treatment, and prevention.

The CRC Digest

Research intelligence for the colorectal cancer community

Get CRC research intelligence delivered weekly — free.

Subscribe

Not Medical Advice

The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.

Content is curated with AI assistance and reviewed by the editorial team.

Read our full disclaimer

Unsubscribe

Subscribe to The CRC Digest

Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe

The CRC Digest provides research summaries for informational and educational purposes only.
This is not medical advice. Always consult your healthcare provider before making any decisions about your care.

Disclaimer Privacy Policy Terms of Use About